875 related articles for article (PubMed ID: 21292848)
1. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
4. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
Sigrist MK; Chiarelli G; Lim L; Levin A
J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Calcium metabolism in health and disease.
Peacock M
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S23-30. PubMed ID: 20089499
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis.
Gutiérrez OM
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957
[TBL] [Abstract][Full Text] [Related]
9. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
10. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
11. The challenge of controlling phosphorus in chronic kidney disease.
Cannata-Andía JB; Martin KJ
Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
[TBL] [Abstract][Full Text] [Related]
12. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
13. [Pathogenesis and treatment of vascular calcification in CKD].
Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
Block GA
Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
[TBL] [Abstract][Full Text] [Related]
15. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
16. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
[TBL] [Abstract][Full Text] [Related]
18. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
Inaguma D; Tatematsu M
Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
[TBL] [Abstract][Full Text] [Related]
19. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D in kidney disease: pathophysiology and the utility of treatment.
Qazi RA; Martin KJ
Endocrinol Metab Clin North Am; 2010 Jun; 39(2):355-63, table of contents. PubMed ID: 20511057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
